Current Event-Free Survival After Sequential Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia

BACKGROUND: Imatinib is an effective tyrosine kinase inhibitor (TKI) for patients with chronic myeloid leukemia (CML) in chronic phase (CP). Although some patients may fail on therapy with imatinib, effective salvage therapy is available with second-generation TKIs. Current measurement of efficacy f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Al-Kali, Aref, Kantarjian, Hagop, Shan, Jianqin, Bassett, Roland, Quintás-Cardama, Alfonso, Borthakur, Gautam, Jabbour, Elias, Verstovsek, Srdan, O’Brien, Susan, Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4327987/
https://ncbi.nlm.nih.gov/pubmed/20845478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25604
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados